geniposide has been researched along with Cancer of Liver in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, S; Tao, S; Wang, Y; Yu, X | 1 |
| Chen, F; Feng, Y; Guo, W; Lao, L; Man, K; Tan, HY; Tsao, SW; Wang, N; Zhang, C; Zhong, Z | 1 |
| Cheung, F; Feng, Y; Hong, M; Lao, L; Nagamatsu, T; Tan, HY; Wang, N | 1 |
3 other study(ies) available for geniposide and Cancer of Liver
| Article | Year |
|---|---|
Geniposide plays anti-tumor effects by down-regulation of microRNA-224 in HepG2 and Huh7 cell lines.
Topics: Apoptosis; beta Catenin; Cell Movement; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Iridoids; Liver Neoplasms; MicroRNAs; Neoplasm Invasiveness; Proto-Oncogene Proteins c-akt | 2020 |
Direct inhibition of the TLR4/MyD88 pathway by geniposide suppresses HIF-1α-independent VEGF expression and angiogenesis in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Endothelial Cells; Hypoxia-Inducible Factor 1, alpha Subunit; Iridoids; Liver Neoplasms; Mice; Myeloid Differentiation Factor 88; Neovascularization, Pathologic; Toll-Like Receptor 4; Vascular Endothelial Growth Factor A | 2020 |
Inhibition of eukaryotic elongation factor-2 confers to tumor suppression by a herbal formulation Huanglian-Jiedu decoction in human hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Berberine; Carcinoma, Hepatocellular; Cell Line, Tumor; Drugs, Chinese Herbal; Elongation Factor 2 Kinase; Female; Flavonoids; Humans; Iridoids; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Phytotherapy; Xenograft Model Antitumor Assays | 2015 |